Palliative Care Group, Inc 765 The City Drive South, Suite 120, Orange, CA, 92868 | |
(562) 746-5061 |
News Archive
When researchers divided out-of-hours general practitioners (GPs) into four groups based on how often they admit their patients to the hospital, they found that if you are seen by a doctor who belongs to the 25 per cent who admit the most often, your chance of a hospital stay is much greater.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.
› Verified 7 days ago
Name | Palliative Care Group, Inc |
---|---|
Location | 765 The City Drive South, Suite 120, Orange, California |
Hospice ID | 751765 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
Accreditation Provider | Community Health Accreditation Partner (CHAP) |
SSA county code | 400 |
News Archive
When researchers divided out-of-hours general practitioners (GPs) into four groups based on how often they admit their patients to the hospital, they found that if you are seen by a doctor who belongs to the 25 per cent who admit the most often, your chance of a hospital stay is much greater.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.
› Verified 7 days ago
NPI Number | 1740611938 |
Organization Name | Palliative Care Group Inc |
Address | 765 The City Drive South Orange, California, 92868 |
Phone Number | (562)746-5061 |
News Archive
When researchers divided out-of-hours general practitioners (GPs) into four groups based on how often they admit their patients to the hospital, they found that if you are seen by a doctor who belongs to the 25 per cent who admit the most often, your chance of a hospital stay is much greater.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.
› Verified 7 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
When researchers divided out-of-hours general practitioners (GPs) into four groups based on how often they admit their patients to the hospital, they found that if you are seen by a doctor who belongs to the 25 per cent who admit the most often, your chance of a hospital stay is much greater.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.
› Verified 7 days ago
Home Health Aides | 0.25 |
Counselors | 0.25 |
Medical Social Workers | 0.25 |
Physicians | 1 |
Registered Nurses | 1 |
Other Personnel | 0.25 |
Total Employees | 3 |
---|
News Archive
When researchers divided out-of-hours general practitioners (GPs) into four groups based on how often they admit their patients to the hospital, they found that if you are seen by a doctor who belongs to the 25 per cent who admit the most often, your chance of a hospital stay is much greater.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.
› Verified 7 days ago
Others | 0.25 |
Total Volunteers | 0.25 |
---|
News Archive
When researchers divided out-of-hours general practitioners (GPs) into four groups based on how often they admit their patients to the hospital, they found that if you are seen by a doctor who belongs to the 25 per cent who admit the most often, your chance of a hospital stay is much greater.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.
› Verified 7 days ago
Seasons Hospice & Palliative Care Of California Location: 750 The City Drive South, Suite 120, Orange, California, 92868 Phone: (562) 746-5061 |
Companion Hospice Location: 2041 W Orangewood Avenue, Orange, California, 92868 Phone: (562) 746-5061 |
Heartland Home Health Care And Hospice Location: 725 W Town & Country Road, Suite 130, Orange, California, 92868 Phone: (562) 746-5061 |
Family Choice Hospice, Inc Location: 2230 West Chapman Ave, Suite 135, Orange, California, 92868 Phone: (562) 746-5061 |